Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

VANDA PHARMACEUTICALS INC. (VNDA)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/21/2018 05/22/2018 05/23/2018 05/24/2018 05/25/2018 Date
16.55(c) 16.6(c) 16.9(c) 17.2(c) 17.25(c) Last
281 010 246 768 428 438 310 296 225 196 Volume
-2.65% +0.30% +1.81% +1.78% +0.29% Change
More quotes
Financials (USD)
Sales 2018 192 M
EBIT 2018 -40,7 M
Net income 2018 -16,7 M
Debt 2018 -
Yield 2018 -
Sales 2019 233 M
EBIT 2019 42,7 M
Net income 2019 17,3 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 49,61
Capi. / Sales2018 4,67x
Capi. / Sales2019 3,84x
Capitalization 896 M
More Financials
Company
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs.It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder.Its product portfolio includes... 
Sector
Biotechnology & Medical Research
Calendar
06/13 | 03:00pmShareholder meeting
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
05/23VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
05/17VANDA PHARMACEUTICALS : to Present at the Deutsche Bank 43rd Annual Health Care ..
AQ
05/08VANDA PHARMACEUTICALS : Reports First Quarter 2018 Financial Results
AQ
05/07VANDA PHARMACEUTICALS : to Present at the Deutsche Bank 43rd Annual Health Care ..
PR
05/02VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
AQ
05/02VANDA : 1Q Earnings Snapshot
AQ
05/02VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
AQ
05/02VANDA PHARMACEUTICALS : Reports First Quarter 2018 Financial Results
PR
04/25VANDA PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K..
AQ
04/25VANDA PHARMACEUTICALS : to Announce First Quarter 2018 Financial Results on May ..
AQ
More news
Sector news : Bio Therapeutic Drugs
05/25The Heated Quest for Opioid Alternatives -2-
DJ
05/25The Heated Quest for Opioid Alternatives
DJ
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/09Drugmaker GSK rings in more change as CFO heads for exit in 2019
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
05/24Day Three of our Free To Focus Live event and we’ve been talking about how cr.. 
05/23$VNDA ALERT: New Vanda Pharmaceuticals Inc. SEC Filing From our Stock News Al.. 
05/23???? Nasdaq CEO and CEO Jim Kelly signed the Listing Certificate! $EVOP
5
05/23On The Fly: Top five analyst initiations $QTNA $KOOL $WTI $TAST $VNDA
1
05/23? Jim Kelly, Chief Executive Officer of takes the stage. We are thrilled to ..
8
More tweets
Qtime:122
News from SeekingAlpha
05/23Vanda's Hetlioz effective in jet lag study 
05/23Premarket analyst action - healthcare 
05/10Vanda Pharmaceuticals (VNDA) Presents At 43rd annual Deutsche Bank Healthcare.. 
05/03HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (05/03/2018) 
05/02Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2018 Results - .. 
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Technical analysis trends VANDA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 20,7 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Secretary & Treasurer
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS INC.13.16%896
GILEAD SCIENCES-5.60%87 807
VERTEX PHARMACEUTICALS4.75%40 001
REGENERON PHARMACEUTICALS-21.45%31 214
GENMAB19.78%11 741
BEIGENE LTD (ADR)97.99%10 063